Telix Pharmaceuticals (TLX) Receivables (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Receivables for 3 consecutive years, with $130.5 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 40.47% to $130.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $130.5 million through Dec 2025, up 40.47% year-over-year, with the annual reading at $130.5 million for FY2025, 40.47% up from the prior year.
  • Receivables for Q4 2025 was $130.5 million at Telix Pharmaceuticals, up from $92.9 million in the prior quarter.
  • The five-year high for Receivables was $130.5 million in Q4 2025, with the low at $43.7 million in Q4 2023.
  • Average Receivables over 3 years is $89.0 million, with a median of $92.9 million recorded in 2024.
  • The sharpest move saw Receivables skyrocketed 112.53% in 2024, then soared 40.47% in 2025.
  • Over 3 years, Receivables stood at $43.7 million in 2023, then surged by 112.53% to $92.9 million in 2024, then skyrocketed by 40.47% to $130.5 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $130.5 million, $92.9 million, and $43.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.